Novartis rises after FDA approves new Femara use
The decision allows Novartis to market Femara to post-menopausal women with early, hormone-positive breast cancer — or patients whose cancer depends on estrogen to grow — as soon as they have had surgery. This is also known as the early adjuvant setting.
cameron diaz
cheap wedding dresses
alyssa milano
state connecticut
como empeso su carrera